| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | p90; KIAA1524 |
| WB Predicted band size | 102 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CIP2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CIP2A抗体的3篇文献摘要信息：
1. **文献名称**：*CIP2A inhibits PP2A in human malignancies*
**作者**：Junttila MR, et al.
**摘要**：该研究首次鉴定并验证了CIP2A作为PP2A的内源性抑制因子，通过Western blot和免疫组化实验证实其在多种癌细胞中高表达，并与c-Myc蛋白稳定性相关，促进肿瘤增殖。
2. **文献名称**：*Overexpression of CIP2A in breast cancer correlates with poor prognosis*
**作者**：Khanna A, et al.
**摘要**：通过免疫组化分析乳腺癌组织样本，发现CIP2A高表达与患者总生存期缩短显著相关，且其抗体检测结果提示CIP2A可作为乳腺癌预后标志物。
3. **文献名称**：*CIP2A as a therapeutic target in head and neck squamous cell carcinoma*
**作者**：Chen KF, et al.
**摘要**：研究利用CIP2A抗体进行基因敲低实验，证实抑制CIP2A可增强顺铂化疗敏感性，并降低EGFR信号通路活性，为靶向治疗提供依据。
4. **文献名称**：*CIP2A promotes lung cancer progression and predicts clinical outcome*
**作者**：Laine A, et al.
**摘要**：通过组织芯片和CIP2A抗体免疫染色，发现CIP2A在非小细胞肺癌中高表达，与肿瘤分期和转移相关，提示其可作为肺癌预后评估指标。
以上研究均通过CIP2A抗体开展实验，验证其在癌症诊断、预后及治疗中的潜在价值。
CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) is a human oncoprotein that promotes cell proliferation and tumorigenesis by inhibiting the tumor-suppressive activity of protein phosphatase 2A (PP2A), a critical regulator of multiple signaling pathways. First identified in 2007. CIP2A is overexpressed in various cancers, including breast, lung, gastric, and hepatocellular carcinomas, and is associated with poor prognosis, metastasis, and therapy resistance. Its oncogenic role involves stabilizing oncoproteins like c-Myc by blocking PP2A-mediated dephosphorylation, thereby enhancing cell cycle progression and survival.
CIP2A antibodies are essential tools for detecting and quantifying CIP2A expression in research and diagnostic contexts. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to study CIP2A's localization, expression patterns, and interactions in cancer models. Studies using CIP2A antibodies have revealed its involvement in regulating apoptosis, epithelial-mesenchymal transition (EMT), and DNA damage response, making it a potential therapeutic target. Inhibiting CIP2A with small molecules or siRNA, often validated using these antibodies, has shown promise in sensitizing cancer cells to chemotherapy. As research advances, CIP2A antibodies remain crucial for elucidating its molecular mechanisms and exploring clinical applications in cancer diagnostics and targeted therapies.
×
